Dermata Therapeutics, Inc. (NASDAQ:DRMAW) Sees Large Decrease in Short Interest

Dermata Therapeutics, Inc. (NASDAQ:DRMAW) was the target of a significant decline in short interest during the month of July. As of July 31st, there was short interest totaling 480 shares, a decline of 88.6% from the July 15th total of 4,197 shares. Based on an average daily volume of 7,524 shares, the days-to-cover ratio is presently 0.1 days.

Dermata Therapeutics Price Performance

Shares of NASDAQ DRMAW traded down $0.00 during midday trading on Thursday, reaching $0.00. The company’s stock had a trading volume of 6,590 shares, compared to its average volume of 10,887. The firm has a 50 day moving average price of $0.01 and a 200-day moving average price of $0.01. Dermata Therapeutics has a 12-month low of $0.00 and a 12-month high of $0.03.

About Dermata Therapeutics

Dermata Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted therapies for inflammatory skin diseases. The company leverages small-molecule approaches to modulate key immune and cellular pathways in dermatologic conditions that currently lack effective or safe long-term treatments. Headquartered in Cambridge, Massachusetts, Dermata is advancing novel programs designed to address both common and severe skin disorders.

The company’s lead pipeline includes a selective topical PI3Kδ inhibitor being evaluated for the treatment of atopic dermatitis, where dysregulated immune signaling drives chronic inflammation and barrier dysfunction.